Evotec SE
Company Profile
Business description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Contact
Essener Bogen 7
Manfred Eigen Campus
Hamburg22419
DEUT: +49 40560810
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
4,766
Stocks News & Analysis
stocks
Overvalued ASX share as market underestimates downside risks
stocks
New production imminent for undervalued ASX gas play
stocks
Going into earnings, is Tesla stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,305.20 | 21.40 | 0.23% |
CAC 40 | 8,174.20 | 14.39 | -0.18% |
DAX 40 | 23,830.99 | 441.20 | -1.82% |
Dow JONES (US) | 46,190.61 | 238.37 | 0.52% |
FTSE 100 | 9,354.57 | 81.52 | -0.86% |
HKSE | 25,859.44 | 612.34 | 2.43% |
NASDAQ | 22,679.97 | 117.44 | 0.52% |
Nikkei 225 | 48,945.44 | 1,363.29 | 2.87% |
NZX 50 Index | 13,324.92 | 35.71 | 0.27% |
S&P 500 | 6,664.01 | 34.94 | 0.53% |
S&P/ASX 200 | 9,010.70 | 22.50 | 0.25% |
SSE Composite Index | 3,866.09 | 26.34 | 0.69% |